Wockhardt share news and announcements
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,801.70down ₹53.80 (2.90%)BSE ₹1,801.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,855.50.
52-week range of traded prices to 23 Oct 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,276 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 71.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,79,19043.6% delivered
Wockhardt share news and announcements
1,008 announcements, routine notices left out, newest first. Page 15 of 21.
Apr 2014
7 Apr · Business
8,000 equity shares of face value of Rs. 5/- each of the Company are allotted to the Independent Directors of the Company pursuant to exercise of stock options.3 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Wockhardt Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Wockhardt Limited has vide its letter inter-alia stated,"Presently we do not believe that there is any information/announcement of the nature sought by you. In the event that there is any development that requires disclosure, we will make the same immediately in accordance with regulatory requirements."
Mar 2014
Feb 2014
10 Feb · Corporate action
Company has fixed Record Date as February 19, 2014 for the purpose of Interim Dividend10 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 09, 2014 has approved re-appointment of Dr. Huzaifa Khorakiwala, Executive Director and Dr. Murtaza Khorakiwala, Managing Director for a period of Five years w.e.f March 31, 2014 subject to the approval of members of the Company.10 Feb · Dividend
Interim dividend will be paid to the shareholders of the Company on or before March 11, 2014.7 Feb · Rating
Credit Analysis & Research Limited (CARE) has assigned a 'CARE A1+' (A One Plus) rating to the short term facilities of the Company, having a tenure upto one year. Instruments with this rating are considered to have a strong degree of safety regarding timely payment of financial obligations and carry lowest credit risk. Further, CARE has assigned a 'CARE AA-' (Double A minus) rating to Company's long term facilities. Instruments with this ratings are considered to have a high degree of safety regarding timely servicing of financial obligations and such instruments carry very low credit risk.
Jan 2014
28 Jan · Board meeting
Inter alia, for the following:(1) To consider and approve the unaudited financial results of the Company for the quarter and nine month ended December 31, 2013 .(2) Consideration of Interim Dividend.
Dec 2013
19 Dec · Updates
Further to our letter dated November 11, 2013, we would like to inform the exchanges that Wockhardt Bio AG, Switzerland has allocated 2,348,000 Ordinary shares of CHF 1.00 each representing 5% of the post diluted capital for subscription at a. price of CHF 5.05 per ordinary share for its initial public offering. The Ordinary shares of Wockhardt Bio AG are scheduled to be listed on December 19, 2013 on the Berne Stock Exchange, Switzerland.
Nov 2013
27 Nov · Updates
Wockhardt Limited has received a Warning Letter from USFDA for its manufacturing units located at L1, Chikalthana, Aurangabad and B15, Waluj, Aurangabad. USFDA has also posted on its website an import alert on the manufacturing unit at L1, Chikalthana, Aurangabad. USFDA has however, excluded five products from import alert. Metoprolol XR is under the import alert. The Company has already initiated several steps to address the observations made by the US FDA and shall put all efforts to resolve the matter at the earliest.11 Nov · Updates
Company is a global pharmaceutical and biotechnology major and has a business of over 75% outside India. The holding Company, for undertaking this is primarily Wockhardt Bio AG, Switzerland. In order to meet long term aspirations of the Company and its group, the Board of Directors of Wockhardt Limited have endorsed the decision of the Board of Wockhardt Bio AG, Switzerland to undertake a European Listing with a relatively modest dilution of approximately 5% of the shareholding of Wockhardt Bio AG, Switzerland.6 Nov · Updates
With reference to earlier announcement dated October 22, 2013 informing the Exchange about the communication received from Medicine and Healthcare Products Regulatory Agency, United Kingdom (Agency) in respect of the Company's manufacturing facility situated at Survey No., 406/4-5-7, Kadaiya, Nani Daman, Wockhardt Ltd has now informed the Exchange that the Company has received another communication from the said Agency whereby they have allowed the Company to manufacture and supply most of the products manufactured at the said facility and assessed to be critical to public health. As a result the net impact on the annualised consolidated revenue is expected to be less than 1 million, out of the total annual consolidated revenue of approximately 18 million, from the said facility.
Oct 2013
25 Oct · Corporate action
Company has fixed Record Date as November 8, 2013 for the purpose of Interim Dividend25 Oct · Dividend
Board of Directors of the Company held on October 25, 2013 have declared an interim Dividend @ 100% i.e. Rs.5/- per share for the financial year 2013-14 on 109,751,153 equity shares of the Company.22 Oct · Updates
Company has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom (UKMHRA), whereby the agency has decided to withdraw the previously issued GMP Certificate to the Company s manufacturing facility situated at Survey No. 106/4-5-7, Kadaiya, Nani Daman and will be issuing a restricted GMP Certificate to the site along with a statement of noncompliance for the said site. In order to avoid market shortage of medically essential products, the GMP certificate will be conditioned to permit continued manufacturing and QC testing of 'critical' products in situations where it has been agreed by the national competent authority or EMA (as appropriate) that there is no feasible alternative in the market concerned. The scope of the statement of non-compliance is therefore limited to medicinal products considered noncritical to public health. Accordingly, the Company shall be able to manufacture and supply from the said facility certain medicinal products critical to public health. The impact of the same on existing business will only be known once the Company receives further communication from UKMHRA. The Company doesn't manufacture any products for the US market at the said manufacturing facility.17 Oct · Updates
With reference to the earlier announcement dated October 12, 2013 about the communication received from Medicine and Healthcare Products Regulatory Agency, United Kingdom (Agency) in respect of the Company's manufacturing facility situated at L1, MIDC Chikalthana, Aurangabad, Wockhardt Ltd has now informed the Exchange that the Company has received another communication from the said Agency whereby they have allowed the Company to manufacture and supply certain products assessed to be critical to public health. The approximate revenue from these products is Pound 3 million from the UK & EU markets to the consolidated revenues of the Company. The Agency has also issued a Drug Alert for recall of certain products, one time impact of which is expected to be approximately Pound 1 million. The Drug Alert specifically mentions that there is no evidence of risk to patient safety from product currently in UK market, however it is considered that the products have not been manufactured in line with GMP requirements.14 Oct · Updates
Company has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom (UKMHRA), whereby the agency has decided to withdraw the previously issued GMP Certificate to the Company's manufacturing facility situated at L1, MIDC, Chikalthana, Aurangabad and will be issuing a restricted GMP Certificate to the site along with a statement of non-compliance for the said site. In order to avoid market shortage of medically essential products, the GMP certificate will be conditioned to permit continued manufacturing and QC testing of 'critical' products in situations where it has been agreed by the national competent authority or EMA (as appropriate) that there is no feasible alternative in the market concerned. The scope of the statement of non-compliance is therefore limited to medicinal products considered non-critical to public health. Accordingly, the Company shall be able to manufacture and supply from the said facility certain medicinal products critical to public health. The impact of the same on existing business will only be known once the Company receives further communication from UKMHRA. The said facility contributes approximately 12 million from the UK and EU markets to the consolidated annual revenues of the Company.11 Oct · Board meeting
Inter alia, for the following:(1) To consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2013 .(2) Consideration of Interim Dividend.8 Oct · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Wockhardt Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Wockhardt Limited has vide its letter inter-alia stated, "We do not believe that there is any information/ announcement of the nature sought by you. In the event that there is any development that requires disclosure, we will make the same immediately in accordance with regulatory requirements."
Sep 2013
Aug 2013
14 Aug · Corporate action
Register of Members and Share Transfer Books (Preference & Equity) of the Company will remain closed from August 24, 2013 to September 2, 2013 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 2, 2013 and declaration of dividend on preference and equity shares of the Company.2 Aug · Board meeting
Inter alia to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2013.
Jul 2013
22 Jul · Updates
In continuation to our Communication dated May 24, 2013, regarding the import alert from the US FDA on the Company's Waluj facility, we wish to communicate that we have received a "warning letter", which lists the observations made during the inspection. The Company has already initiated several corrective actions to resolve the same.Our earlier clarification on the implications of the import alert on the Company's consolidated revenues for the current financial year remain unchanged. If any additional measures are necessary, the Company would take them to squarely address all concerns. The Company continues to cooperate with FDA to resolve the issues at the earliest
May 2013
27 May · Dividend
Board of Directors of the Company at its meeting held on May 27, 2013, inter alia, has transacted the following business:(1) The Board recommended dividend @ 0.01% (Rs. 0.0005 per preference share of Rs. 5/- each) absorbing a sum of Rs. 298,557/- on 475,659,941 Non-Convertible Cumulative Redeemable Preference shares of Rs. 5/- each and 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares of Rs. 5/- each. The dividend, if declared at the Annual General Meeting, will be paid within 30 days from the date of Annual General Meeting.(2). The Board recommended dividend of Rs. 5/- per equity share of Rs. 5/- each (i.e. @ 100%) on equity shares of the Company for the year 2012-2013. The dividend, if declared at the Annual General Meeting, will be paid within 30 days from the date of Annual General Meeting.27 May · Board meeting
Board of Directors of the Company at its meeting held on May 27, 2013 has considered appointment of Mr. V. Suresh as "President - Finance" of the Company.24 May · Updates
Company has received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad. The impact of the import alert on the revenues is estimated to be in the range of $100m on an annualised basis. The Company is taking all steps to address the concerns raised by USFDA and shall put all efforts to resolve the issue at the earliest.13 May · Board meeting
Inter alia, to consider and approve the following: (1) Approval of the Audited Consolidated and Standalone financial results of the Company for the quarter and year ended March 31, 2013. (2) Recommendation of dividend on preference shares and equity shares. Further the Company has informed that, in the Audit Committee meeting scheduled to be held on, May 27, 2013, the appointment of Mr. V. Suresh as President - Finance will also be considered.